Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Survey Shows One In Five Patients With Parkinson’s Disease And Troublesome Symptoms Should Be ...

13.12.2007
... Considered For Deep-Brain Stimulation

Findings from a new observational survey show that around one in five patients with troublesome symptoms related to Parkinson's disease may benefit from deep-brain stimulation (DBS) and should be considered for the treatment.1

The survey was conducted in four European countries (Belgium, Germany, Italy, Spain) and Canada with the support of a new screening program, STIMULUS, that has the potential to help neurologists identify patients who could benefit from DBS. The results were presented today at the 17th World Congress on Parkinson’s disease and Related Disorders (WCPD) in Amsterdam.(1)

“Deep-brain stimulation has been proven to be a very effective solution for certain patients with Parkinson’s disease, who have not achieved an acceptable level of control over their motor symptoms with medication alone” stated Doctor Jan Herzog, Department of Neurology, Christian-Albrechts-Universität in Kiel, Germany and member of the expert panel that developed the STIMULUS program.

“However, the complexity of Parkinson’s disease makes it very challenging for general neurologists to identify the appropriate candidates for DBS. Good patient selection is critical to get the most effective results with deep-brain stimulation” added Doctor Herzog.

There are over one million patients with Parkinson’s disease in Europe.(2) However, a large number of patients who could benefit from DBS are never referred, and as many as 63 percent of those who are referred disappointingly find out that they are not eligible for the procedure.(3)

Currently patients receive DBS treatment on average 14 years after the diagnosis of Parkinson’s disease.(4) At that stage, the severity of the disease has already significantly impaired social and professional activities. The data presented today show that this patient screening program can assist general neurologists in identifying patients to be referred for evaluation for DBS before the disease progression limits the potential benefits. With accurate patient and referral to specialist centres over 100,000 patients with Parkinson’s disease in Europe could be considered for DBS treatment, which may help get their symptoms under control and significantly improve their quality of life.(2) (5)

DBS in Parkinson’s Disease
The benefits of DBS have been shown in clinical trials in patients with Parkinson’s disease. Results from a randomised trial show that DBS combined with medication significantly improves quality of life compared to conventional medical treatment alone.(6) Additionally, DBS has been shown to improve motor symptoms substantially and maintain overall function for at least five years in patients with advanced Parkinson’s disease.(7) A recent literature review shows that DBS is the most efficacious treatment for improving quality of life in patients with Parkinson’s disease.(8)

“Deep-brain stimulation is a treatment that has been shown to improve both motor function and quality of life in patients with Parkinson’s disease” said Stephen Pickard, President of the European Parkinson’s Disease Awareness (EPDA). “Enabling people to regain control of their body and undertake tasks with increased independence not only improves their physical well-being but also greatly improves the emotional health of both the person with Parkinson’s and their family/carers.”

STIMULUS Survey Results
The survey presented at WCPD was conducted among 106 neurologists in Belgium, Germany, Italy, Spain and Canada, who screened 1,530 patients with the help of the STIMULUS program.(1) This is a computer-based patient screening program developed by an independent international panel of 12 movement disorders experts, (including Doctor Herzog) who identified five absolute criteria that a patient with Parkinson’s disease must meet, plus an additional seven relative clinical variables, that determine if a patient should be referred for treatment with DBS.1 The STIMULUS program was developed for use in Europe and enables neurologists to quickly and accurately determine a patient’s suitability to be considered for treatment.1()

Survey results found that of the patients examined, 70 percent fulfilled the five absolute criteria and almost two thirds of these were confirmed as eligible for DBS consideration when assessed against the relative variables. The most prevalent reasons cited for patients to not be eligible for DBS consideration were insufficiently severe motor symptoms, mental contraindications and medical conditions preventing surgery.(1)

•The STIMULUS program was developed using the scientifically validated RAND Appropriateness method (a modified Delphi method). This combines best available scientific evidence with the collective judgement of experts. DBS is considered appropriate when the expected benefits for the patient outweigh any possible negative effects by a sufficient margin that the procedure is worth doing. The STIMULUS program can be accessed online at http://test.stimulus-dbs.org.
•STIMULUS Program Screening Criteria:
Absolute CriteriaRelative Variables
Idiopathic Parkinson’s disease patientAge
Severe motor disabilityDuration of Parkinson’s disease
Insufficient response to treatment with levadopaSeverity of OFF symptoms
Not having any medical condition that prevents surgerySeverity of dyskinesias
Not having a medically resistant mental diseaseLevadopa-resistant axial symptoms
Refractory tremor
Intellectual impairment
•Deep-brain stimulation is a mild electrical stimulation in the brain which influences movement control. It is considered safe and has been shown to be well-tolerated in patients in the short and long term.9 It is an adjustable and reversible procedure that does not damage the brain tissue.10,11

•In Europe, DBS has been developed and marketed by Medtronic, Inc. under the name Activa® Therapy since 1993.

Medtronic, Inc. (www.medtronic.com - NYSE: MDT), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

References

1.Herzog J, Allert N et al. First experiences with a decision tool to support appropriate referral for DBS in patients with Parkinson’s disease. 12 December 2007. Poster 3.206. Presented WCPD, Amsterdam.
2.De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. “Prevalence of Parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted
3.Okun MS et al. Neurology. 2004; 63:161-163.
4.Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R et al. nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006; 21(Suppl 14): S290–304
5.European Parkinson’s Disease Association Conference. Participation in Life Survey Results 1999. Krakow, Poland. 1999. Accessed: http://www.epda.eu.com/publicationsDirectory/epdaPubArchive.shtm# 29 November 2007
6.Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355(9): 896–908
7.Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al. Five year follow up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Eng J Medicine. 2003; 349 (20): 1925-1934.
8.Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson’s disease. Movement Disorders. 2007; 22(6): 757-765.
9.Halpern C, Hurtig H, Jaggi J, Grossman M, Won M, Baltuch G. Deep-brain stimulation in neurological disorders. Parkinsonism Relat Disord. 2007 13(1): 1-16.
10.NICE Guidance: Deep-brain stimulation for Parkinson’s disease. Issue date: November 2003.

11.Volkmann J, Benecke R. Deep-brain stimulation for dystonia: patient selection and evaluation. Mov Disord. 2002; 17 (Suppl 3): S112-S115.

Fiona Walton | alfa
Further information:
http://www.cohnwolfe.com
http://test.stimulus-dbs.org

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>